198 related articles for article (PubMed ID: 24913448)
1. LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.
Frietsch JJ; Kastner C; Grunewald TG; Schweigel H; Nollau P; Ziermann J; Clement JH; La Rosée P; Hochhaus A; Butt E
Oncotarget; 2014 Jul; 5(14):5257-71. PubMed ID: 24913448
[TBL] [Abstract][Full Text] [Related]
2. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
Salgia R; Uemura N; Okuda K; Li JL; Pisick E; Sattler M; de Jong R; Druker B; Heisterkamp N; Chen LB
J Biol Chem; 1995 Dec; 270(49):29145-50. PubMed ID: 7493940
[TBL] [Abstract][Full Text] [Related]
3. Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
Herrmann AB; Müller ML; Orth MF; Müller JP; Zernecke A; Hochhaus A; Ernst T; Butt E; Frietsch JJ
J Cell Mol Med; 2020 Mar; 24(5):2942-2955. PubMed ID: 31957290
[TBL] [Abstract][Full Text] [Related]
4. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
Nichols GL; Raines MA; Vera JC; Lacomis L; Tempst P; Golde DW
Blood; 1994 Nov; 84(9):2912-8. PubMed ID: 7524758
[TBL] [Abstract][Full Text] [Related]
5. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation.
ten Bosch GJ; Kessler JH; Blom J; Joosten AM; Gambacorti-Passerini C; Melief CJ; Leeksma OC
Br J Haematol; 1998 Dec; 103(4):1109-15. PubMed ID: 9886328
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia.
Butt E; Stempfle K; Lister L; Wolf F; Kraft M; Herrmann AB; Viciano CP; Weber C; Hochhaus A; Ernst T; Hoffmann C; Zernecke A; Frietsch JJ
Cells; 2020 Feb; 9(2):. PubMed ID: 32075106
[TBL] [Abstract][Full Text] [Related]
8. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
[TBL] [Abstract][Full Text] [Related]
9. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
ten Hoeve J; Arlinghaus RB; Guo JQ; Heisterkamp N; Groffen J
Blood; 1994 Sep; 84(6):1731-6. PubMed ID: 7521685
[TBL] [Abstract][Full Text] [Related]
11. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin.
Oda A; Miyakawa Y; Druker BJ; Ishida A; Ozaki K; Ohashi H; Wakui M; Handa M; Watanabe K; Okamoto S; Ikeda Y
Blood; 1996 Dec; 88(11):4304-13. PubMed ID: 8943867
[TBL] [Abstract][Full Text] [Related]
12. CRKL binding to BCR-ABL and BCR-ABL transformation.
Kolibaba KS; Bhat A; Heaney C; Oda T; Druker BJ
Leuk Lymphoma; 1999 Mar; 33(1-2):119-26. PubMed ID: 10194128
[TBL] [Abstract][Full Text] [Related]
13. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
Kardinal C; Konkol B; Schulz A; Posern G; Lin H; Adermann K; Eulitz M; Estrov Z; Talpaz M; Arlinghaus RB; Feller SM
FASEB J; 2000 Aug; 14(11):1529-38. PubMed ID: 10928987
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
15. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
Xu N; Ouyang Z; DU QF; Wang S; Yang J; Wang Y; Liu XL
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):25-8. PubMed ID: 21429397
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation of murine Crkl.
de Jong R; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Oncogene; 1995 Oct; 11(8):1469-74. PubMed ID: 7478571
[TBL] [Abstract][Full Text] [Related]
18. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
ten Hoeve J; Kaartinen V; Fioretos T; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Cancer Res; 1994 May; 54(10):2563-7. PubMed ID: 8168080
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl.
de Jong R; van Wijk A; Haataja L; Heisterkamp N; Groffen J
J Biol Chem; 1997 Dec; 272(51):32649-55. PubMed ID: 9405482
[TBL] [Abstract][Full Text] [Related]
20. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
